使用地尼白介素-妥索罗汀进行的抑制细胞清除免疫疗法是一种有效的针对结核病的宿主导向疗法。
Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.
作者信息
Gupta Shashank, Cheung Laurene, Pokkali Supriya, Winglee Kathryn, Guo Haidan, Murphy John R, Bishai William R
机构信息
Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland.
National Emerging Infectious Diseases Laboratories Institute, Boston University, Massachusetts.
出版信息
J Infect Dis. 2017 Jun 15;215(12):1883-1887. doi: 10.1093/infdis/jix208.
Abstract
Host-directed therapies that augment host immune effector mechanisms may serve as important adjunctive therapies for tuberculosis treatment. We evaluated the activity of denileukin diftitox in an acute mouse model of tuberculosis (TB) infection and analyzed the cellular composition and bacterial burden in lungs and spleens. These in vivo studies show that denileukin diftitox potentiates standard TB treatment in the mouse model, an effect which may be due to depletion of T-regulatory and myeloid-derived suppressor cells during TB infection. Our results indicate that denileukin diftitox and other suppressor cell-depleting therapies may be useful adjunctive, host-directed therapies for TB.
摘要
增强宿主免疫效应机制的宿主导向疗法可能成为结核病治疗的重要辅助疗法。我们在急性小鼠结核病感染模型中评估了地尼白介素（denileukin diftitox）的活性，并分析了肺和脾中的细胞组成及细菌负荷。这些体内研究表明，地尼白介素在小鼠模型中可增强标准结核病治疗效果，这一效应可能归因于结核病感染期间调节性T细胞和髓源性抑制细胞的耗竭。我们的结果表明，地尼白介素及其他抑制细胞耗竭疗法可能是有用的辅助性宿主导向结核病治疗方法。
相似文献
1
Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis.使用地尼白介素-妥索罗汀进行的抑制细胞清除免疫疗法是一种有效的针对结核病的宿主导向疗法。
J Infect Dis. 2017 Jun 15;215(12):1883-1887. doi: 10.1093/infdis/jix208.
2
Effective Host-Directed Therapy for Tuberculosis by Depletion of Myeloid-Derived Suppressor Cells and Related Cells Using a Diphtheria Toxin Fusion Protein.利用白喉毒素融合蛋白耗竭髓系来源的抑制细胞和相关细胞实现结核病的有效宿主导向治疗。
J Infect Dis. 2021 Dec 1;224(11):1962-1972. doi: 10.1093/infdis/jiab235.
3
Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.预先给予地尼白介素妥西罗汀作为体内调节性T细胞清除剂，以增强犬同种异体造血干细胞移植模型中的疫苗接种效果。
Vet Immunol Immunopathol. 2012 Jan 15;145(1-2):233-40. doi: 10.1016/j.vetimm.2011.11.009. Epub 2011 Nov 25.
4
IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.白细胞介素-2免疫毒素地尼白介素-妥西毒素可减少调节性T细胞并增强疫苗介导的T细胞免疫。
Blood. 2007 Nov 1;110(9):3192-201. doi: 10.1182/blood-2007-06-094615. Epub 2007 Jul 6.
5
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.用地尼白介素-妥昔单抗（ONTAK）进行腹腔内免疫治疗复发性难治性卵巢癌。
Gynecol Oncol. 2024 Dec;191:74-79. doi: 10.1016/j.ygyno.2024.09.019. Epub 2024 Oct 2.
6
Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma.白细胞介素-2与白喉毒素的融合蛋白（地尼白介素-布舍瑞林，DAB389IL-2，昂他克）无法清除黑色素瘤患者体内的调节性T淋巴细胞。
J Immunother. 2005 Nov-Dec;28(6):582-92. doi: 10.1097/01.cji.0000175468.19742.10.
7
An evaluation of denileukin diftitox for the treatment of relapsed or refractory cutaneous T-cell lymphoma.一项关于地尼白介素妥西罗汀治疗复发或难治性皮肤T细胞淋巴瘤的评估。
Expert Opin Biol Ther. 2025 Jul;25(7):687-694. doi: 10.1080/14712598.2025.2517853. Epub 2025 Jun 14.
8
Denileukin diftitox.地尼白介素-妥昔单抗
Am J Clin Dermatol. 2000 Jan-Feb;1(1):67-72; discussion 73. doi: 10.2165/00128071-200001010-00008.
9
Xpert MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance.用于肺外结核病和利福平耐药性的Xpert MTB/RIF检测
Cochrane Database Syst Rev. 2018 Aug 27;8(8):CD012768. doi: 10.1002/14651858.CD012768.pub2.
10
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
引用本文的文献
1
The Research Progress in Immunotherapy of Tuberculosis.结核病免疫治疗的研究进展。
Front Cell Infect Microbiol. 2021 Nov 15;11:763591. doi: 10.3389/fcimb.2021.763591. eCollection 2021.
2
Immunotherapy With 5, 15-DPP Mediates Macrophage M1 Polarization and Modulates Subsequent Infectivity in rBCG30 Immunized Mice.5,15-DPP 免疫疗法介导巨噬细胞 M1 极化并调节 rBCG30 免疫小鼠的后续感染性。
Front Immunol. 2021 Oct 29;12:706727. doi: 10.3389/fimmu.2021.706727. eCollection 2021.
3
Effective Host-Directed Therapy for Tuberculosis by Depletion of Myeloid-Derived Suppressor Cells and Related Cells Using a Diphtheria Toxin Fusion Protein.利用白喉毒素融合蛋白耗竭髓系来源的抑制细胞和相关细胞实现结核病的有效宿主导向治疗。
J Infect Dis. 2021 Dec 1;224(11):1962-1972. doi: 10.1093/infdis/jiab235.
4
Host-Directed Therapies: Modulating Inflammation to Treat Tuberculosis.宿主导向疗法：调节炎症以治疗结核病。
Front Immunol. 2021 Apr 19;12:660916. doi: 10.3389/fimmu.2021.660916. eCollection 2021.
5
Host-directed therapy to combat mycobacterial infections.针对分枝杆菌感染的宿主导向治疗。
Immunol Rev. 2021 May;301(1):62-83. doi: 10.1111/imr.12951. Epub 2021 Feb 9.
6
The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review.将免疫调节药物重新用于辅助化疗治疗结核病的前景：批判性综述
Antibiotics (Basel). 2021 Jan 19;10(1):91. doi: 10.3390/antibiotics10010091.
7
Monocytic myeloid-derived suppressor cells reflect tuberculosis severity and are influenced by cyclooxygenase-2 inhibitors.单核细胞来源的髓样抑制细胞反映了结核病的严重程度，并受环氧化酶-2 抑制剂的影响。
J Leukoc Biol. 2021 Jul;110(1):177-186. doi: 10.1002/JLB.4A0720-409RR. Epub 2020 Nov 6.
8
Host-Pathogen Interaction as a Novel Target for Host-Directed Therapies in Tuberculosis.宿主-病原体相互作用作为结核病宿主导向治疗的新靶点。
Front Immunol. 2020 Jul 21;11:1553. doi: 10.3389/fimmu.2020.01553. eCollection 2020.
9
Target the Host, Kill the Bug; Targeting Host Respiratory Immunosuppressive Responses as a Novel Strategy to Improve Bacterial Clearance During Lung Infection.靶向宿主，消灭细菌；针对宿主呼吸免疫抑制应答作为一种新策略改善肺部感染期间的细菌清除。
Front Immunol. 2020 Apr 30;11:767. doi: 10.3389/fimmu.2020.00767. eCollection 2020.
10
Therapies for tuberculosis and AIDS: myeloid-derived suppressor cells in focus.结核病和艾滋病的治疗方法：聚焦髓源性抑制细胞。
J Clin Invest. 2020 Jun 1;130(6):2789-2799. doi: 10.1172/JCI136288.
本文引用的文献
1
Versatile myeloid cell subsets contribute to tuberculosis-associated inflammation.多功能髓样细胞亚群促成了结核病相关炎症。
Eur J Immunol. 2015 Aug;45(8):2191-202. doi: 10.1002/eji.201545493.
2
Lung-residing myeloid-derived suppressors display dual functionality in murine pulmonary tuberculosis.肺驻留髓系来源的抑制细胞在小鼠肺结核中具有双重功能。
Am J Respir Crit Care Med. 2014 Nov 1;190(9):1053-66. doi: 10.1164/rccm.201405-0828OC.
3
Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.维拉帕米作为外排抑制剂辅助治疗加速结核病治疗。
Am J Respir Crit Care Med. 2013 Sep 1;188(5):600-7. doi: 10.1164/rccm.201304-0650OC.
4
Pathogen-specific Treg cells expand early during mycobacterium tuberculosis infection but are later eliminated in response to Interleukin-12.分枝杆菌感染早期特异性 Treg 细胞扩增，但随后在白细胞介素 12 的作用下被消除。
Immunity. 2013 Jun 27;38(6):1261-70. doi: 10.1016/j.immuni.2013.06.003. Epub 2013 Jun 20.
5
A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.一项多中心 II 期临床试验，旨在确定联用替伊莫单抗和环磷酰胺、多柔比星、长春新碱和泼尼松治疗未经治疗的外周 T 细胞淋巴瘤的安全性和疗效：CONCEPT 研究。
Leuk Lymphoma. 2013 Jul;54(7):1373-9. doi: 10.3109/10428194.2012.742521. Epub 2013 Jan 29.
6
Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas.调节性 T 细胞在视网膜母细胞瘤的髓系来源抑制细胞中刺激 B7-H1 的表达。
J Invest Dermatol. 2012 Apr;132(4):1239-46. doi: 10.1038/jid.2011.416. Epub 2011 Dec 22.
7
Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma.Ⅱ期临床试验中，采用调节性 T 细胞耗竭剂，地尼白介素脱噬毒素，治疗不可切除的 IV 期黑色素瘤患者。
BMC Cancer. 2011 Dec 13;11:515. doi: 10.1186/1471-2407-11-515.
8
Therapeutic enhancement of protective immunity during experimental leishmaniasis.实验性利什曼病期间保护性免疫的治疗增强。
PLoS Negl Trop Dis. 2011 Sep;5(9):e1316. doi: 10.1371/journal.pntd.0001316. Epub 2011 Sep 6.
9
A pilot study of denileukin diftitox (DD) in combination with high-dose interleukin-2 (IL-2) for patients with metastatic renal cell carcinoma (RCC).一项关于联用德尼单抗（DD）和高剂量白细胞介素-2（IL-2）治疗转移性肾细胞癌（RCC）患者的初步研究。
J Immunother. 2010 Sep;33(7):716-22. doi: 10.1097/CJI.0b013e3181e4752e.
10
Expansion and function of Foxp3-expressing T regulatory cells during tuberculosis.结核感染期间表达Foxp3的调节性T细胞的扩增与功能
J Exp Med. 2007 Sep 3;204(9):2159-69. doi: 10.1084/jem.20062105. Epub 2007 Aug 20.
Zotero 插件